Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
BridgeBio Pharma Inc has a consensus price target of $43.17 based on the ratings of 20 analysts. The high is $70 issued by Cantor Fitzgerald on September 16, 2024. The low is $19 issued by SVB Leerink on January 23, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Leerink Partners, and Scotiabank on October 25, 2024, October 17, 2024, and October 16, 2024, respectively. With an average price target of $44.33 between HC Wainwright & Co., Leerink Partners, and Scotiabank, there's an implied 73.99% upside for BridgeBio Pharma Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for BridgeBio Pharma (NASDAQ:BBIO) was reported by HC Wainwright & Co. on October 25, 2024. The analyst firm set a price target for $43.00 expecting BBIO to rise to within 12 months (a possible 68.76% upside). 37 analyst firms have reported ratings in the last year.
The latest analyst rating for BridgeBio Pharma (NASDAQ:BBIO) was provided by HC Wainwright & Co., and BridgeBio Pharma reiterated their buy rating.
There is no last upgrade for BridgeBio Pharma
The last downgrade for BridgeBio Pharma Inc happened on July 18, 2023 when Jefferies changed their price target from $24 to $33 for BridgeBio Pharma Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on October 25, 2024 so you should expect the next rating to be made available sometime around October 25, 2025.
While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $43.00 to $43.00. The current price BridgeBio Pharma (BBIO) is trading at is $25.48, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.